Dicos

Quick links to important sections

Dicos

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dicos

Property Description
Active Ingredient Diconazole
Form Oral Capsule or Tablet
Pharmacological Class Systemic Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common Use Pain and Inflammation Relief
Origin Synthetic

Dicos is a pharmaceutical preparation containing the active ingredient Diconazole, primarily classified as a systemic non-steroidal anti-inflammatory drug (NSAID). Its general therapeutic purpose is the symptomatic relief of pain and inflammation, and it is clinically recognized for its potent analgesic and anti-inflammatory action. This means the medicine works by effectively reducing pain and swelling responses throughout the body.

Diconazole, the INN (International Nonproprietary Name), is an established member of the NSAID family, commonly used to address pain and discomfort associated with musculoskeletal issues, such as joint stiffness or muscle strain.


Composition and Origin of Dicos

Dicos is typically manufactured as an oral capsule or modified-release tablet intended for systemic administration (swallowing). The Diconazole active substance is a fully synthetic organic compound, created through controlled chemical synthesis in a laboratory setting. This synthetic origin ensures a consistent and predictable pharmacological profile.

The differentiating feature of the Dicos formulation often lies in its enteric coating or specialized release technology. This design element helps protect the active ingredient from degradation in the stomach and aims to improve overall patient tolerance compared to immediate-release formulations.


What Type of Condition is Dicos Intended to Treat?

Dicos is generally intended to address inflammatory and painful conditions, particularly those affecting the joints, muscles, or soft tissues. NSAIDs are widely used for managing symptomatic relief in conditions like osteoarthritis.

Its therapeutic focus is strictly on analgesia (pain relief) and anti-inflammation. The medicine is used to quickly reduce the severity of symptoms associated with various acute and chronic issues, serving as a key element of supportive care.

What side effects are possible with Dicos?

Possible side effects and safety information

This information describes the documented safety profile and officially recognized adverse reactions of Dicos (diclofenac) as defined in regulatory documents. It does not include advice, instructions for use, or therapeutic benefits.

Serious Safety Risks and Contraindications

The safety profile is primarily defined by the potential for serious, life-threatening events in specific body systems. Regulatory authorities issue mandatory warnings concerning:

  • Cardiovascular Thrombotic Events: The medicine carries a risk for serious, potentially fatal events such as heart attack (myocardial infarction) and stroke. This risk can increase with higher doses and longer durations of treatment.
  • Serious Gastrointestinal Events: Severe gastrointestinal issues, including inflammation, bleeding, ulceration, and perforation of the stomach or intestines, have been documented and can be fatal. This risk is present throughout treatment.
  • Hepatotoxicity: Rare but serious liver reactions, including liver failure, necrosis, and fulminant hepatitis, have been reported.

Contraindications (Situations Where Use is Restricted):

The medicine is officially contraindicated (should not be used) for patients with:

  • A history of asthma, hives, or other allergic-type reactions after taking aspirin or other NSAIDs.
  • Established congestive heart failure (NYHA Class II-IV), specific established ischemic heart disease, peripheral arterial disease, or cerebrovascular disease.
  • Use during the setting of coronary artery bypass graft (CABG) surgery.
  • Active gastrointestinal bleeding or ulceration.

Other Documented Adverse Reactions

Adverse reactions are classified by frequency based on clinical trials and post-marketing data. Common reactions (occurring in 1% to 10% of users) frequently involve the gastrointestinal system and may include nausea, dyspepsia, abdominal pain, and flatulence. Other system-organ classes involved include the nervous system (e.g., headache, dizziness) and the hepato-biliary system (e.g., elevations in liver enzymes).

Dose and Exposure Considerations

Official safety guidance notes that the lowest effective dose should be used for the shortest duration necessary to minimize the potential risk for adverse cardiovascular and gastrointestinal events.

Overdose and Emergency Response

The official regulatory profile for Dicos (Diconazole) overdose focuses on documenting both common manifestations and potential systemic complications. Overdose may present with generally reversible signs affecting the Gastrointestinal and Central Nervous Systems (CNS), including nausea, vomiting, epigastric pain, drowsiness, and lethargy.


Overdose and When to Seek Help: Official Regulatory Information

Documented Overdose Presentations: Overdose may present with signs affecting the gastrointestinal tract and the CNS, including nausea, vomiting, epigastric pain, drowsiness, and lethargy. Severe outcomes listed are acute renal failure, hypertension, gastrointestinal bleeding, respiratory depression, and coma.

Emergency-Response Statements: Patients must seek medical attention immediately if any signs of a serious event occur, such as chest pain, sudden weakness, or slurred speech. Contacting a poison control center is a required initial action.

Management and Constraints: Management is symptomatic and supportive, as no specific antidote is known. Regulatory documents state that activated charcoal or an osmotic cathartic may be used, but only following the ingestion of a large overdose or if the patient is seen within four hours. Hospital monitoring for complications is implied. Procedural instructions for supportive measures also include differing doses for pediatric patients compared to adults. The regulatory basis emphasizes the potential for severe or life-threatening outcomes.

Therapeutic Uses of Dicos

What Dicos Treats: Main Uses and Benefits

Dicos (Diconazole), generally considered relevant as a systemic NSAID, is applied across domains where additional symptomatic support is needed, focusing on symptomatic relief and anti-inflammatory support. These agents may be considered relevant for managing acute or chronic conditions where symptoms related to inflammatory or irritative states are present. This provides support that helps ease the overall symptom burden during difficult episodes.

Dicos is commonly used to help with acute or disruptive episodes where short-term symptomatic assistance is needed, including muscle strains, ligament sprains, post-operative discomfort, osteoarthritis, and rheumatoid arthritis. It helps address symptom clusters that may become disruptive, such as chronic joint stiffness and pain.

“The focus is on providing supportive relief when symptoms interfere with routine activities, and may assist with maintaining functional stability.”


Quick Fact: Symptomatic Support for Inflammatory Conditions

Dicos is applied in addressing conditions characterized by periods of fluctuating manifestations, specifically easing manifestations like symptoms that become more disruptive during flare-ups and swelling, which contributes to easing the overall symptom load during symptomatic periods.

Regulatory References

  1. NIH StatPearls on NSAIDs Overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Dicos? — Official Regulatory Information

The eligibility for Dicos (Diconazole) is strictly defined by regulatory documents, which establish the populations for whom use is contraindicated or restricted.

Eligibility Scope Status Defined by Label
Populations for whom use is allowed Primarily adult patients (typically ge 18 years) for approved systemic indications.
Populations for whom use is contraindicated Patients with known hypersensitivity to NSAIDs, history of aspirin-induced asthma, or immediately following CABG surgery.
Age-related eligibility rules Pediatric use is generally not established. Geriatric patients (ge 65 years) must be monitored closely due to increased labeled risks.
Pregnancy and lactation eligibility Contraindicated from 30 weeks gestation and later. Use is restricted and generally avoided between 20 and 30 weeks gestation. Excreted into human milk.

Condition-Specific Eligibility Rules:

Use must be avoided or severely limited in patients with advanced renal disease, severe heart failure, or severe hepatic impairment. Individuals with a prior history of gastrointestinal bleeding or peptic ulcers are at a significantly increased risk for serious events and require extreme caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Dicos (Diconazole), a systemic NSAID, around pharmacokinetic modulation and heightened pharmacodynamic risks. Dicos is formally contraindicated for treating perioperative pain following Coronary Artery Bypass Graft (CABG) surgery and is prohibited in patients with a history of allergic reactions to other NSAIDs.

Pharmacokinetic and Clearance Alterations

Co-administration with the strong inhibitor Voriconazole causes a significant pharmacokinetic interaction, officially documented to increase Dicos exposure (AUC) by 78% and maximum concentration (Cmax) by 114%. Furthermore, Dicos reduces the renal clearance of substances like Lithium and Methotrexate, which can lead to increased plasma levels of these co-administered drugs.

Pharmacodynamic Risks and Constraints

Concomitant use with Anticoagulants (e.g., Warfarin), Anti-platelet Agents (e.g., Aspirin), or SSRIs increases the documented pharmacodynamic risk of gastrointestinal bleeding or ulceration. Dicos can also diminish the antihypertensive effect of ACE Inhibitors and ARBs. This combination poses a heightened risk of renal function deterioration, particularly noted for the elderly, volume-depleted, or those with existing renal impairment. Additionally, specific oral formulations require administration on an empty stomach to prevent a documented reduction in efficacy when taken with food.

Mechanism of Action

The mechanism of Dicos involves intervention within the body's eicosanoid signaling systems, targeting chemical pathways that exhibit heightened activity under specific physiological conditions. Its mechanistic action is based on enzyme activity modulation at the molecular level, which generates a cascade of suppressed signaling that alters subsequent physiological responses.

Targeting the Cyclooxygenase Enzyme System

This domain defines the specific molecular targets: the Cyclooxygenase (COX-1 and COX-2) enzymes. Dicos acts as a competitive inhibitor, binding reversibly to these enzymes to block their ability to convert the substrate arachidonic acid into prostaglandins. This fundamental molecular interaction limits the initiation rate of the downstream signaling sequence.

Modulation of Inflammatory Mediator Production

This step characterizes the mechanistic consequence of enzyme inhibition within the prostaglandin synthesis pathway. The COX inhibition results in a decrease in the local concentration of pro-inflammatory mediators, altering the magnitude of chemical signals that drive the inflammatory cascade.

Alteration of Nociceptor Sensitization

This domain focuses on the physiological consequence of reduced chemical signaling within the nervous system. The mechanism decreases prostaglandin concentration proximate to nociceptors, which alters their chemical sensitization state and elevates the input threshold necessary for signal propagation.

Dosage and Administration Information

Dicos is approved exclusively for oral administration, typically provided as a capsule or modified-release tablet intended for systemic absorption. Guidelines define precise parameters for its use, ensuring consistency across various clinical scenarios. The administration of Dicos adheres to protocols that dictate route, schedule, and patient-specific adjustments.


Administration Protocol and Dosage

The standard regimen for Dicos typically involves a starting dose of 50 mg, with the usual maintenance dose ranging from 50 mg to 100 mg. The total intake must not exceed the maximum daily dose, which is established between 150 mg and 200 mg, depending on the specific formulation being used. The drug is administered either once daily or in divided doses up to three times per day to provide consistent therapeutic levels.


Intake Conditions and Handling

A mandatory instruction is that Dicos must be taken with food or a full glass of water to minimize potential gastrointestinal irritation associated with systemic Non-Steroidal Anti-Inflammatory Drugs. For all modified-release or enteric-coated dosage forms, the tablet or capsule must be swallowed whole and should not be crushed, broken, or chewed, as this compromises the intended drug release profile.


Population-Specific Use

A lower initial dose is used when treating older adults to minimize systemic exposure. Furthermore, dose adjustments or avoidance are mandatory for patients diagnosed with severe renal or hepatic impairment, reflecting the need to account for altered drug clearance in these specific groups. Treatment should adhere to the principle of using the lowest effective dose for the shortest possible duration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dicos

Dicos (Diconazole) was evaluated in studies exploring outcomes related to symptoms associated with specific painful and inflammatory conditions. The available research primarily consists of Randomized Controlled Trials (RCTs), where patients are assigned to receive Dicos, a placebo, or a different active medicine, alongside broader systematic reviews that combine findings from multiple studies. Research has examined short-term symptomatic changes and patient-reported measures of discomfort.


Evidence for Symptomatic Relief in Osteoarthritis

Research for Dicos in osteoarthritis was studied for research exploring symptom changes, particularly those affecting the knee and hand. These studies primarily involved adults with the condition. The goal of this research was to explore how outcomes related to physical discomfort changed over time and how patterns evolved in measures reflecting daily functioning or activity level, using tools like the WOMAC index. Studies described measurements of symptomatic changes in pain and function compared to a control or comparator over defined follow-up periods. The evidence base provides limited insight into the maintenance of symptomatic changes beyond the short-term trial periods, and research is not designed to assess whether Dicos influences the underlying progression of Osteoarthritis.


Evidence for Symptomatic Relief in Rheumatoid Arthritis

Research focused on how the medicine was observed in studies examining outcomes linked to inflammatory or irritative states, such as measurements of joint swelling and tenderness, as well as patient-reported perceived discomfort. Trials examined symptomatic endpoints, such as changes in patient-reported pain and stiffness over follow-up periods that were typically medium-term (up to six months). However, the existing research does not provide evidence concerning the medicine's potential to modify or halt the long-term course of Rheumatoid Arthritis itself.


The Research Landscape: Key Uncertainties and Gaps

Several key research gaps persist across the evidence base. Long-term effects are not fully established regarding the sustained nature of symptomatic change, as many trials are short-term. The evidence base is focused strictly on symptomatic changes and does not include research that examined whether the medicine has any effect on the underlying mechanisms of chronic disease. Comparative evidence (head-to-head trials) is lacking for certain pairings of Dicos versus all available alternative treatments.

Frequently Asked Questions (FAQ)

Common questions about Dicos (FAQ)


Q: How long does Dicos typically take to start showing an effect?

A: According to official product information for this class of medicine, the onset of pain relief can begin relatively quickly, often starting within the first hour after taking the dose. However, the time it takes to feel the maximum intended effect may be longer.


Q: What is the usual duration of a Dicos course of treatment?

A: Treatment duration for Dicos varies depending on the medical condition it addresses. Regulatory guidance emphasizes that treatment is typically guided to use the lowest effective dose for the shortest possible duration. Specific label limits on treatment length exist and are defined based on the condition being treated.


Q: What should I do if I notice a common side effect of Dicos?

A: For common and expected side effects listed in the official documents, patient information typically suggests monitoring the symptoms. Official patient information often emphasizes that patients inform a healthcare provider of any new or persistent common side effects during routine follow-up appointments.


Q: Does Dicos interact with common over-the-counter pain relievers?

A: Official documents detail many specific drug interactions. While other medicines in the same class (non-steroidal anti-inflammatory drugs) are a major concern, some common pain relievers, such as acetaminophen, are not typically listed as having a major direct interaction risk with Dicos. Regulatory safety information emphasizes the importance of disclosing all over-the-counter medicines to a healthcare provider for a complete review.


Q: Can Dicos be taken at the same time as other prescription medications?

A: Due to the potential for significant drug-drug interactions, regulatory documents require that patients inform their healthcare provider of all other prescription medications currently being taken. This ensures that the interaction profile can be properly evaluated.


Q: Are there any specific foods I should avoid while on Dicos?

A: The official label specifies that the medicine is administered with food or a full glass of water to help minimize potential gastrointestinal irritation. Generally, there are no broad food groups that are strictly prohibited or listed as needing to be avoided in the medicine's official patient labeling.


Q: Can Dicos affect my ability to drive or operate machinery?

A: Official safety guidance warns that due to documented adverse reactions such as dizziness and headache, activities requiring full concentration, such as driving or operating machinery, may be impacted until the individual understands how the medicine affects them.


Q: Are there any contraindications listed for Dicos, and what does 'contraindication' mean?

A: A contraindication is a term defined in official medical documents as a specific condition or factor that makes the use of a medicine improper or inadvisable. This is because using the medicine under these circumstances carries a high risk of harm that outweighs any potential benefit.


Q: Is Dicos considered safe for people over 65 years old?

A: Official product information indicates that the treatment protocol for older adults includes close monitoring and typically involves a lower initial dose. This is because this population has a heightened risk of serious adverse events documented on the label, particularly issues affecting the kidneys and the digestive system.


Q: Where can I find the official prescribing information for Dicos?

A: The most comprehensive and accessible official source for information is the Medication Guide (or Patient Information Leaflet). This document is provided by the manufacturer and contains all key factual and safety information as approved by regulatory bodies.


Q: What should I do if I think Dicos is causing me new symptoms?

A: Official patient instructions and warnings emphasize that immediate contact with a healthcare provider is required if new or worsening symptoms are experienced. This mandatory disclosure is particularly important for symptoms related to the serious risks listed on the label, such as difficulty breathing or severe stomach pain.


Q: Is there a generic version of Dicos available?

A: The generic status of the active ingredient, Diconazole, is published in official drug listings maintained by national regulatory authorities. These sources track and publish all approved brand name and generic drug products.


Q: Is it possible for side effects from Dicos to appear after I stop taking it?

A: Official documents describe that Dicos has a defined half-life, which determines how long the substance remains in the body. Because of this, the drug's effects, including the potential for adverse reactions, can persist for several days after the final dose has been taken.


Q: Does Dicos interact with any dietary supplements or vitamins?

A: Official drug information does not typically include comprehensive data regarding interactions with all dietary supplements or vitamins. Regulatory safety guidance requires patients to disclose all supplements being taken alongside Dicos to their healthcare provider for a complete review.


Q: Is it safe to consume alcohol while taking Dicos?

A: While official documents may not list a direct chemical interaction, combining Dicos and alcohol may increase the risk of experiencing serious side effects. This combination can particularly affect the liver and may heighten central nervous system effects such as dizziness.


Q: Does Dicos interact with grapefruit or grapefruit juice?

A: Official labeling for certain medications may include specific warnings about avoiding grapefruit or grapefruit juice. This is because these foods can interfere with the way some drugs are metabolized (processed by the body), which can potentially lead to a higher concentration of the medicine in the blood.


Q: Does Dicos cause dependency or withdrawal symptoms if stopped suddenly?

A: Official regulatory documents include a section that addresses Abuse and Dependence potential. This medicine is not typically categorized as having the potential to cause psychological or physical dependence.


Q: Why is Dicos only available by prescription?

A: The status of Dicos as a prescription-only medicine is determined by regulatory bodies based on its high-risk safety profile. The potential for serious adverse events requires ongoing medical oversight and patient monitoring that is not possible with an over-the-counter medication.


Q: What does it mean if my Dicos tablet looks slightly different in size or color?

A: All approved drug products are required to meet strict standards for physical appearance regarding color, size, and imprint. If your tablet looks different, it may indicate a switch to a generic formulation or a different approved manufacturer. This fact can be confirmed by checking official drug identifier databases.


Q: What is the best way to handle a dose of Dicos that was missed?

A: Patient information leaflets generally provide instructions for missed doses. Typically, the guidance found in these leaflets states that if it is almost time for the next scheduled dose, the individual should skip the missed dose and resume the regular schedule.


Q: Are there any tests recommended to check if Dicos is working properly?

A: Regulatory guidance for Dicos often establishes a treatment protocol that includes the monitoring of specific laboratory tests before and periodically during treatment. This is due to the documented potential for the medicine to affect organ function, such as the liver (requiring liver function tests) and the kidneys.


Q: Is Dicos known to affect sleep patterns?

A: Official safety information lists certain central nervous system effects, including headache and dizziness, as possible adverse reactions. If these occur, they may indirectly impact an individual's sleep quality or overall feeling of restfulness.


Q: What are the known risks of discontinuing Dicos without medical guidance?

A: Since Dicos is used for the symptomatic relief of pain and inflammation, the main and most common consequence of discontinuing its use is the return of the underlying symptoms that it was treating.


Q: How long after taking Dicos can I safely take another medicine with a known interaction risk?

A: The time required to safely introduce a new medication is determined by the medicine’s clearance rate and half-life (the time it takes for the substance to leave the body). This specific time window is a factual data point documented in the Clinical Pharmacology section of the official label.

How should Dicos be stored and disposed of?

Storage Requirements

Dicos must be stored at Controlled Room Temperature, defined by regulatory bodies as 20 C to 25 C (68 F to 77 F). The official label permits temporary temperature excursions between 15 C and 30 C (59 F and 86 F). The product must be protected from moisture to maintain its stability, and it is explicitly required not to freeze the medicine.

The capsules or tablets must remain in the original container with the child-resistant cap tightly closed. The medicine must be stored out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Disposal of unused or expired Dicos should prioritize official drug take-back programs or mail-back envelopes when available. If a take-back option is not accessible, the medicine may be discarded in the household trash. This requires mixing the Dicos with an undesirable substance, such as used coffee grounds or dirt, and placing the mixture in a sealed container before disposal. Do not flush Dicos down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Dicos found in:

A-Z Index: